Clinical trial AG013-ODOM-201
A Phase 2, multi-center, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of topically-applied AG013 for the attenuation of oral mucositis in subjects with cancers of the head and neck receiving concomitant chemoradiation therapy
| Cancers | |
|---|---|
| Organ | Head and Neck |
| Trial status | Trial closed |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 2 |
| Academic trial | Non |
| Sponsor | Oragenics |
| EudraCT Identifier | 2016-004161-68 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT03234465 |
| Inclusion criteria | No prior gene therapy |
| Last update |